NEW YORK (GenomeWeb News) – Asterand said today that it has extended its drug-discovery and development collaboration with Bristol-Myers Squibb for up to three years.
Under the agreement, BMS will continue to have access to Asterand's PhaseZERO drug-discovery services and XpressBANK human tissue and clinical sample bank for early drug-target validation and compound optimization.
BMS may also use Asterand's ProCURE custom clinical sample collection service, Asterand said.